Literature DB >> 34893529

SAMHD1 Promotes the Antiretroviral Adaptive Immune Response in Mice Exposed to Lipopolysaccharide.

BradleyS Barrett1, David H Nguyen1, Joella Xu2, Kejun Guo1, Shravida Shetty1, Sean T Jones1,3, Kaylee L Mickens1,3, Caitlin Shepard2, Axel Roers4, Rayk Behrendt4, Li Wu5, Baek Kim2,6, Mario L Santiago7,3.   

Abstract

SAMHD1 is a potent HIV-1 restriction factor that blocks reverse transcription in monocytes, dendritic cells and resting CD4+ T cells by decreasing intracellular dNTP pools. However, SAMHD1 may diminish innate immune sensing and Ag presentation, resulting in a weaker adaptive immune response. To date, the role of SAMHD1 on antiretroviral immunity remains unclear, as mouse SAMHD1 had no impact on murine retrovirus replication in prior in vivo studies. Here, we show that SAMHD1 significantly inhibits acute Friend retrovirus infection in mice. Pretreatment with LPS, a significant driver of inflammation during HIV-1 infection, further unmasked a role for SAMHD1 in influencing immune responses. LPS treatment in vivo doubled the intracellular dNTP levels in immune compartments of SAMHD1 knockout but not wild-type mice. SAMHD1 knockout mice exhibited higher plasma infectious viremia and proviral DNA loads than wild-type mice at 7 d postinfection (dpi), and proviral loads inversely correlated with a stronger CD8+ T cell response. SAMHD1 deficiency was also associated with weaker NK, CD4+ T and CD8+ T cell responses by 14 dpi and weaker neutralizing Ab responses by 28 dpi. Intriguingly, SAMHD1 influenced these cell-mediated immune (14 dpi) and neutralizing Ab (28 dpi) responses in male but not female mice. Our findings formally demonstrate SAMHD1 as an antiretroviral factor in vivo that could promote adaptive immune responses in a sex-dependent manner. The requirement for LPS to unravel the SAMHD1 immunological phenotype suggests that comorbidities associated with a "leaky" gut barrier may influence the antiviral function of SAMHD1 in vivo.
Copyright © 2022 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34893529      PMCID: PMC8755609          DOI: 10.4049/jimmunol.2001389

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  82 in total

1.  SAMHD1 Limits HIV-1 Antigen Presentation by Monocyte-Derived Dendritic Cells.

Authors:  Diana Ayinde; Timothée Bruel; Sylvain Cardinaud; Françoise Porrot; Julia G Prado; Arnaud Moris; Olivier Schwartz
Journal:  J Virol       Date:  2015-07       Impact factor: 5.103

2.  Vpx overcomes a SAMHD1-independent block to HIV reverse transcription that is specific to resting CD4 T cells.

Authors:  Hanna-Mari Baldauf; Lena Stegmann; Sarah-Marie Schwarz; Ina Ambiel; Maud Trotard; Margarethe Martin; Manja Burggraf; Gina M Lenzi; Helena Lejk; Xiaoyu Pan; Oliver I Fregoso; Efrem S Lim; Libin Abraham; Laura A Nguyen; Frank Rutsch; Renate König; Baek Kim; Michael Emerman; Oliver T Fackler; Oliver T Keppler
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-22       Impact factor: 11.205

3.  Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology.

Authors:  Jean-Philippe Michaud; Maxime Hallé; Antoine Lampron; Peter Thériault; Paul Préfontaine; Mohammed Filali; Pascale Tribout-Jover; Anne-Marie Lanteigne; Rachel Jodoin; Christopher Cluff; Vincent Brichard; Rémi Palmantier; Anthony Pilorget; Daniel Larocque; Serge Rivest
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-15       Impact factor: 11.205

Review 4.  Sexual dimorphism in autoimmunity.

Authors:  Kira Rubtsova; Philippa Marrack; Anatoly V Rubtsov
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

Review 5.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

6.  The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation.

Authors:  Tommy E White; Alberto Brandariz-Nuñez; Jose Carlos Valle-Casuso; Sarah Amie; Laura Anh Nguyen; Baek Kim; Marina Tuzova; Felipe Diaz-Griffero
Journal:  Cell Host Microbe       Date:  2013-04-17       Impact factor: 21.023

7.  Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection.

Authors:  Kalani Halemano; Kejun Guo; Karl J Heilman; Bradley S Barrett; Diana S Smith; Kim J Hasenkrug; Mario L Santiago
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

8.  Mice of the resistant H-2(b) haplotype mount broad CD4(+) T cell responses against 9 distinct Friend virus epitopes.

Authors:  Ronald J Messer; Kerry J Lavender; Kim J Hasenkrug
Journal:  Virology       Date:  2014-04-05       Impact factor: 3.616

9.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection.

Authors:  Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

Review 10.  Evolutionary conflicts between viruses and restriction factors shape immunity.

Authors:  Nisha K Duggal; Michael Emerman
Journal:  Nat Rev Immunol       Date:  2012-09-14       Impact factor: 53.106

View more
  1 in total

1.  Altered Immunoglobulin Repertoire and Decreased IgA Somatic Hypermutation in the Gut during Chronic HIV-1 Infection.

Authors:  Sean T Jones; Kejun Guo; Emily H Cooper; Stephanie M Dillon; Cheyret Wood; David H Nguyen; Guannan Shen; Bradley S Barrett; Daniel N Frank; Miranda Kroehl; Edward N Janoff; Katerina Kechris; Cara C Wilson; Mario L Santiago
Journal:  J Virol       Date:  2022-08-08       Impact factor: 6.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.